Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly making false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, leading to investor losses during the class period from December 27, 2023, to May 6, 2025 [7]. Allegation Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, stating it would occur in the second half of 2025, while failing to disclose risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [7]. - On May 6, 2025, it was revealed that the company had discussions with the FDA regarding safety monitoring but chose to submit the NDA without a REMS, which misled investors about the regulatory timeline [7]. Next Steps - Investors who purchased Cytokinetics shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/cytokinet ...

[You may also click here for additional information] NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) and reminds investors of the November 17, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=17 ...

Core Viewpoint - Cytokinetics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the timeline for the New Drug Application (NDA) submission and approval process for its drug aficamten [2][3]. Group 1: Company Overview - Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors for treating diseases that compromise muscle performance [1]. Group 2: Legal Allegations - The class action was filed on behalf of shareholders who purchased Cytokinetics securities between December 27, 2023, and May 6, 2025, claiming that the company misled them about the NDA submission timeline for aficamten [2]. - The complaint states that during the class period, Cytokinetics made materially false statements regarding the expected FDA approval for aficamten, which was anticipated in the second half of 2025, and failed to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [3]. Group 3: Next Steps for Shareholders - Shareholders interested in participating in the class action must submit their papers by November 17, 2025, to serve as lead plaintiff, representing other class members in the litigation [4].

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=173217&from=3 CLASS ...

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 5, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ ...

Cytokinetics is involved in a securities fraud class action lawsuit due to alleged misleading statements about drug development timelines.Executive Vice President of Research & Development at Cytokinetics sold 2,105 shares amid the ongoing lawsuit.The company's financials show a negative P/E ratio of -11.38, a high price-to-sales ratio of 80.64, and a current ratio of 6.76, indicating mixed financial health.Cytokinetics, Incorporated (NASDAQ: CYTK) is a biopharmaceutical company focused on developing muscle ...

Cantor Fitzgerald reiterated an "Overweight" rating for NASDAQ:CYTK, indicating confidence in the stock's future performance.Cytokinetics announced the granting of stock options and RSUs to new employees, aligning their interests with shareholders.The stock price of $59.35 reflects a 1.56% increase, showcasing positive market sentiment towards Cytokinetics.Cytokinetics, Incorporated, trading on the NASDAQ under the symbol CYTK, is a biopharmaceutical company focused on developing muscle biology-driven treat ...

CYTK investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration ("FDA") for its NDA for aficamten in the second half of 2025, base ...